ストックスクリーナーアプリを入手
2.44
0.41%
-0.01
アフターアワーズ：
2.37
-0.07
-2.87%
前日終値:
$2.45
開ける：
$2.41
24時間の取引高:
6,676
Relative Volume:
0.20
時価総額：
$6.94M
収益：
-
当期純損益:
$-29.77M
株価収益率:
-2.4158
EPS:
-1.01
ネットキャッシュフロー:
$-24.23M
1週間 パフォーマンス:
-6.87%
1か月 パフォーマンス:
+3.39%
6か月 パフォーマンス:
-51.39%
1年 パフォーマンス:
-68.17%
1日の値動き範囲:
$2.37
$2.4629
1週間の範囲:
$2.36
$2.6576
52週間の値動き範囲:
$2.115
$15.75
Moleculin Biotech Inc Stock (MBRX) Company Profile
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
Moleculin Biotech Inc (MBRX) 最新ニュース
Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast - Longview News-Journal
Moleculin Biotech (NASDAQ:MBRX) Earns Sell Rating from Analysts at StockNews.com - Defense World
Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin - Star Local Media
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML - GuruFocus.com
Soft Tissue Sarcoma Market Growth to Accelerate in Forecast - openPR
Moleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.com - Defense World
Moleculin Biotech stockholders approve new stock plan By Investing.com - Investing.com South Africa
Moleculin to Participate in the Virtual Investor Lunch Break: Th - GuruFocus.com
Moleculin Abstract Accepted for Poster Presentation at the Europ - GuruFocus.com
Moleculin Biotech stockholders approve new stock plan - Investing.com India
Moleculin Biotech’s Annual Meeting Decisions and Elections - TipRanks
Moleculin Biotech (NASDAQ:MBRX) versus Equillium (NASDAQ:EQ) Financial Comparison - Defense World
Moleculin Biotech Highlights Annamycin’s AML Treatment Potential - Yahoo Finance
Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available - Financial Times
Ependymoma Market to Rise by 2032, DelveInsight | Fera - openPR
StockNews.com Begins Coverage on Moleculin Biotech (NASDAQ:MBRX) - Defense World
Moleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: Pivotal Phase 3 Trial for ... - Yahoo Finance
Moleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: P - GuruFocus.com
Moleculin Announces Proposed Underwritten Public Offering - Marketscreener.com
Moleculin Announces Full Exercise of Over-Allotment Option - Marketscreener.com
Moleculin Biotech Hosts Virtual AML KOL Event and Trial Update - TipRanks
Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024 - Marketscreener.com
Moleculin Biotech (NASDAQ:MBRX) Now Covered by StockNews.com - Defense World
Moleculin to Present at Two Upcoming Investor Conferences - Marketscreener.com
Moleculin Biotech (NASDAQ:MBRX) Now Covered by Analysts at StockNews.com - Defense World
Moleculin Biotech Releases Updated Corporate Presentation - TipRanks
Moleculin Biotech (NASDAQ:MBRX) Receives New Coverage from Analysts at StockNews.com - Defense World
Moleculin Biotech Shares Rise 12% After Positive Annamycin Data - MarketWatch
Moleculin Biotech Sees Positive Data From Annamycin Study - MarketWatch
Moleculin Biotech’s Annamycin Shows Promise in Cancer Treatment - TipRanks
Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma - PR Newswire
Kendall Capital Management Buys 305 Shares of McKesson Co. (NYSE:MCK) - Defense World
Playstudios CFO sells $39,500 in stock By Investing.com - Investing.com Canada
Mitcham shares upgraded to outperform on value after preferred conversion - Investing.com India
Medipharm Labs Shares Jump on Clearing Remaining Debt - MarketWatch
MediPharm Labs Announces $2.1M Debt Repayment - Financial Times
Moleculin Biotech CEO Discusses Clinical Trials and Drug Development - TipRanks
Moleculin Biotech Shares Insights in Corporate Update - TipRanks
Moleculin Participates in Virtual Investor "What this Means" Segment - PR Newswire
Moleculin Participates in Virtual Investor "What this Means" Segment – Company Announcement - Financial Times
Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated at StockNews.com - Defense World
Moleculin Biotech Advances Phase 2 Glioblastoma Study - TipRanks
Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma - Marketscreener.com
Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StreetInsider.com
Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - PR Newswire
Moleculin Biotech Raises Capital with Public Offering - TipRanks
Moleculin Announces Closing of up to $16.5 Million Public Offering - Financial Times
Q3 2024 EPS Estimates for Moleculin Biotech, Inc. (NASDAQ:MBRX) Cut by Analyst - Defense World
Moleculin Biotech (NASDAQ:MBRX) Stock Passes Below Fifty Day Moving Average of $3.45 - Defense World
Moleculin Biotech Secures Funding for Drug Development Programs - TipRanks
Moleculin Prices of up to $16.5 Million Public Offering - citybiz
Moleculin Biotech Inc (MBRX) 財務データ
収益
当期純利益
現金流量
EPS
Moleculin Biotech Inc (MBRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| George Robert E. | Director |
Dec 26 '23 |
Buy |
0.69 |
14,493 |
10,000 |
14,660 |
| KLEMP WALTER V | CEO and President |
Dec 26 '23 |
Buy |
0.69 |
188,404 |
129,999 |
680,880 |
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):